Thalidomide-4-O-CH2-COO(t-Bu)

Overview

Thalidomide -4-O-CH2-COO(t-Bu) is t-Bu modified Thalidomide ( HY-14658 ), which is the final step intermediate in the synthesis of Thalidomide -4-OH ( HY-123096 ). Thalidomide -4-O-CH2-COO(t-Bu) acts as a Cereblon ligand to recruit CRBN proteins. The t-Bu protecting group at the end of Thalidomide -4-O-CH2-COO(t-Bu) can be removed under acidic conditions to participate in the synthesis of PROTAC molecules. Thalidomide -4-O-CH2-COO(t-Bu) is a key intermediate in the synthesis of CRBN-based designed PROTAC molecules.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > E3 Ligase Ligand-Linker Conjugates | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-42771
• CAS No.: 1950635-36-5
• Molecular Formula: C19H20N2O7
• Molecular Weight: 388.37
• Purity: 99.26%
• Storage: Store at room temperature 3 years. In solvent -80°C, 2 years , -20°C, 1 year
• Availability: In-stock

Source

Original product source